Table 1.
Characteristics of Patients (n=448).
| Characteristic | NLR<2.81 | NLR≥2.81 | p | PLR<168.24 | PLR≥168.24 | p | LMR<5.46 | LMR≥5.46 | p |
|---|---|---|---|---|---|---|---|---|---|
| N | 335 | 113 | 247 | 201 | 347 | 101 | |||
| Sex | 0.114 | 0.101 | < 0.001 | ||||||
| female | 146 (32.6%) | 39 (8.7%) | 93 (20.8%) | 92 (20.5%) | 128 (28.6%) | 57 (12.7%) | |||
| male | 189 (42.2%) | 74 (16.5%) | 154 (34.4%) | 109 (24.3%) | 219 (48.9%) | 44 (9.8%) | |||
| Age | 1.000 | 0.006 | 1.000 | ||||||
| <60 | 175 (39.1%) | 59 (13.2%) | 114 (25.4%) | 120 (26.8%) | 181 (40.4%) | 53 (11.8%) | |||
| ≥60 | 160 (35.7%) | 54 (12.1%) | 133 (29.7%) | 81 (18.1%) | 166 (37.1%) | 48 (10.7%) | |||
| BMI | 0.237 | 0.007 | 0.101 | ||||||
| <25 | 243 (54.2%) | 89 (19.9%) | 170 (37.9%) | 162 (36.2%) | 264 (58.9%) | 68 (15.2%) | |||
| ≥25 | 92 (20.5%) | 24 (5.4%) | 77 (17.2%) | 39 (8.7%) | 83 (18.5%) | 33 (7.4%) | |||
| Tumor Site | 0.003 | < 0.001 | 0.045 | ||||||
| Colon | 166 (37.1%) | 75 (16.7%) | 114 (25.4%) | 127 (28.3%) | 196 (43.8%) | 45 (10%) | |||
| Rectum | 169 (37.7%) | 38 (8.5%) | 133 (29.7%) | 74 (16.5%) | 151 (33.7%) | 56 (12.5%) | |||
| Tumor Size | 0.001 | 0.005 | 0.064 | ||||||
| <5 | 202 (45.1%) | 48 (10.7%) | 153 (34.2%) | 97 (21.7%) | 185 (41.3%) | 65 (14.5%) | |||
| ≥5 | 133 (29.7%) | 65 (14.5%) | 94 (21%) | 104 (23.2%) | 162 (36.2%) | 36 (8%) | |||
| Stage | 0.520 | 0.117 | 0.263 | ||||||
| I+II | 191 (42.6%) | 69 (15.4%) | 152 (33.9%) | 108 (24.1%) | 196 (43.8%) | 64 (14.3%) | |||
| III+IV | 144 (32.1%) | 44 (9.8%) | 95 (21.2%) | 93 (20.8%) | 151 (33.7%) | 37 (8.3%) | |||
| Grade | 0.202 | 0.988 | 0.905 | ||||||
| G1+G2 | 316 (70.5%) | 102 (22.8%) | 231 (51.6%) | 187 (41.7%) | 323 (72.1%) | 95 (21.2%) | |||
| G3+M | 19 (4.2%) | 11 (2.5%) | 16 (3.6%) | 14 (3.1%) | 24 (5.4%) | 6 (1.3%) | |||
| NVI | 0.454 | 0.699 | 0.494 | ||||||
| No | 208 (46.4%) | 65 (14.5%) | 153 (34.2%) | 120 (26.8%) | 208 (46.4%) | 65 (14.5%) | |||
| Yes | 127 (28.3%) | 48 (10.7%) | 94 (21%) | 81 (18.1%) | 139 (31%) | 36 (8%) | |||
| CEA | 0.770 | 0.685 | 1.000 | ||||||
| <6.5 | 241 (53.8%) | 79 (17.6%) | 174 (38.8%) | 146 (32.6%) | 248 (55.4%) | 72 (16.1%) | |||
| ≥6.5 | 94 (21%) | 34 (7.6%) | 73 (16.3%) | 55 (12.3%) | 99 (22.1%) | 29 (6.5%) | |||
| CA19-9 | 0.682 | 0.468 | 0.420 | ||||||
| <27 | 266 (59.4%) | 87 (19.4%) | 191 (42.6%) | 162 (36.2%) | 270 (60.3%) | 83 (18.5%) | |||
| ≥27 | 69 (15.4%) | 26 (5.8%) | 56 (12.5%) | 39 (8.7%) | 77 (17.2%) | 18 (4%) | |||
| Chemotherapy | 0.030 | 0.002 | 0.821 | ||||||
| No | 178 (39.7%) | 46 (10.3%) | 140 (31.2%) | 84 (18.8%) | 172 (38.4%) | 52 (11.6%) | |||
| Yes | 157 (35%) | 67 (15%) | 107 (23.9%) | 117 (26.1%) | 175 (39.1%) | 49 (10.9%) |
NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; BMI, body mass index; M, Mucinous adenocarcinoma; NVI, nerve or vascular invasion; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19–9.